Alivus Life Sciences Limited — PPTs, 24-10-2024: Investor Presentation

Glenmark Life Sciences Limited shared its Q2 FY25 financial results, reporting revenues of ₹5,069 million, a decline of 13.9% QoQ and 14.9% YoY. However, gross margins improved to 55.6%. EBITDA was ₹1,429 million, indicating a 13.4% QoQ decrease. The company anticipates a stronger second half, supported by a solid order book and improved product mix. Strong cash flow of ₹1,340 million during H1 FY25 bolstered cash equivalents to ₹4,461 million.